Monge-Ortega Olga Patricia, Domínguez-Ortega Javier, González-Muñoz Miguel, Cabañas Rosario, Lluch-Bernal Magdalena, Fiandor Ana, Bravo-Gallego Luz Yadira, Quirce Santiago
Hospital San Juan de Dios, Departamento de Alergia. San José, Costa Rica.
Rev Alerg Mex. 2017 Oct-Dec;64(4):505-508. doi: 10.29262/ram.v64i4.312.
Amlodipine is one of the third generation dihydropyridine calcium channel blockers used for hypertension. Mild, moderate and severe reactions have been reported with calcium channel blockers. Cross-reactivity among these drugs has not been established.
We have presented the case of a patient who developed a delayed pruritic, and erythematous maculopapular skin exanthema after the intake of amlodipine. A positive lymphocyte transformation test (LTT) confirmed the implication of amlodipine in the reaction and showed positivity to another calcium channel blocker, nifedipine, demonstrating cross reactivity.
This is the first reported case of hypersensitivity to amlodipine in which the involvement of the drug is confirmed by a positive TTL. TTL could become a good diagnostic alternative for patients who experience late reactions to amlodipine and possibly cross-reactivity with nifedipine.
氨氯地平是用于治疗高血压的第三代二氢吡啶类钙通道阻滞剂之一。钙通道阻滞剂已报告有轻度、中度和重度反应。这些药物之间的交叉反应尚未明确。
我们报告了一例患者，在服用氨氯地平后出现延迟性瘙痒性红斑丘疹性皮肤疹。阳性淋巴细胞转化试验（LTT）证实了氨氯地平与该反应有关，并显示对另一种钙通道阻滞剂硝苯地平呈阳性反应，表明存在交叉反应。
这是首例经阳性TTL证实药物参与的氨氯地平超敏反应报告病例。对于经历氨氯地平迟发反应且可能与硝苯地平存在交叉反应的患者，TTL可能成为一种良好的诊断选择。
